Johnson & Johnson's venture arm backs Francis Medical for prostate cancer push
What's the deal? Francis Medical has entered a late-stage financing agreement led by Johnson & Johnson's corporate venture arm, Johnson & Johnson Innovation — JJDC. The Maple Grove, Minnesota medical device company makes the Vanquish System, a minimally invasive thermotherapy platform that ablates targeted prostate tissue using water vapor energy. The amount was not disclosed.
What's the endgame? The capital funds two tracks: scaling commercial infrastructure, physician training, and market access to drive Vanquish adoption; and supporting the company through a planned Premarket Approval (PMA) submission to the FDA for managing clinically localized prostate cancer.
Why now? Vanquish received FDA 510(k) clearance in November 2025, and procedures have since expanded to multiple states. "This is a pivotal moment in Francis Medical's evolution as we prepare to transition from a limited commercial launch to a broader U.S. market presence," said president and chief executive officer Mike Kujak.
The deal follows an $80 million Series C in January 2025 and marks a notable investor in Johnson & Johnson's venture arm as the company moves from early launch toward wider commercialization.
What's the evidence? Vanquish is backed by the VAPOR 2 pivotal study, a prospective, multicenter, single-arm trial enrolling 235 intermediate-risk patients across 26 US sites. Initial results from the first 110 patients, published in The Journal of Urology , showed 91% had no clinically significant MRI-visible cancer in the treated area after a single procedure, with no device-related serious adverse events. The study will follow patients to five years.
What could go wrong? Early findings do not yet establish long-term cancer outcomes or the broader indication Francis is pursuing. The FDA has cleared Vanquish only as a tool for thermal ablation of prostate tissue, not for treating any disease, and the single-arm study remains in follow-up to support the planned PMA submission.
Piper SandlerDealroom has a profile for this one. Try Dealroom → served as exclusive financial advisor to Francis Medical.
The signal: A strategic investment from a medtech giant's venture arm signals growing confidence in minimally invasive, tissue-preserving prostate cancer treatment — even as the regulatory and clinical bar for a full disease indication remains years away.
Read more: tickertech.com
Image credit: Generated with Gemini